When:
Thursday, May 25, 2017
12:00 PM - 12:45 PM CT
Where: Robert H Lurie Medical Research Center, Searle Seminar Room (Ground Floor), 303 E. Superior, Chicago, IL 60611 map it
Contact:
Bryan Morrison
(312) 503-1927
Group: Medical Humanities & Bioethics Lunchtime Montgomery Lectures
Category: Lectures & Meetings
The Master of Arts in Medical Humanities and Bioethics program presents
A Montgomery Lecture
with
Mark Sheldon, PhD
Assistant Dean
Weinberg College of Arts and Sciences
Northwestern University
Distinguished Senior Lecturer
Department of Philosophy
Weinberg College of Arts and Sciences
Northwestern University
Faculty in the Medical Humanities and Bioethics Program
Northwestern University Feinberg School of Medicine
Ethics Consult Service
Department of Religion, Health and Human Values
Rush University Medical Center
Chicago, Illinois
We Should Talk About Futility, But How?
Futility is an idea that comes and goes with varying importance. At one point it was viewed as very important as a means of responding to the way the right to refuse treatment seemed to morph into the right to demand treatment. But then it appears to have disappeared. I want to argue that we should bring the term back, make robust use of it, but as we do this we need to be clear about the appropriate circumstance in which to use the term.
When:
Thursday, June 1, 2017
12:00 PM - 12:45 PM CT
Where: Robert H Lurie Medical Research Center, Searle Seminar Room (Ground Floor), 303 E. Superior, Chicago, IL 60611 map it
Contact:
Bryan Morrison
(312) 503-1927
Group: Medical Humanities & Bioethics Lunchtime Montgomery Lectures
Category: Lectures & Meetings
The Master of Arts in Medical Humanities & Bioethics Program presents
A Montgomery Lecture
with
Megan Crowley-Matoka, PhD
Associate Professor, Medical Education
Faculty, Medical Humanities & Bioethics Graduate Program
Member, Center for Bioethics and Medical Humanities
Northwestern University Feinberg School of Medicine
Opioids, Epidemics, and the Rise of the Urine Drug Screen
Chronic pain has been at the center of entwined crises in the contemporary U.S. concerning both the under- and the over-treatment of pain. Steeply climbing rates of overdose deaths involving prescription painkillers created intense pressure to change pain management practices. One of the most immediate and widespread responses to this pressure has been a dramatically increased reliance on a time-worn, rather humble form of patient surveillance: the urine drug screen (UDS). This talk will explore some of the unanticipated effects of this reinvigorated role for UDS as they unfold "on the ground" in patient experience, clinical relations, and public policy.